Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: Arthritis Care Res (Hoboken). 2015 Sep;67(9):1210–1218. doi: 10.1002/acr.22580

Figure 1.

Figure 1

Benefit Structure for Ambulatory Biologic Drug Coverage in the Medicare Program in 2009.

The present study examines biologic drug use for rheumatoid arthritis under Part B and Part D insurance, shaded in gray.

*Under certain circumstances, Part B may provide coverage for some self-administered immunosuppressive therapies, erythropoietin for dialysis patients, osteoporosis drugs for certain homebound patients, certain oral cancer drugs, and certain drugs necessary to use Durable Medical Equipment.

**Catastrophic Coverage is the greater of $6 or 5% once beneficiaries reach a certain spending threshold ($4,350 in 2009).